Cancer Forums and News by PhD's


News | Forums Register

Go Back   Cancer Forums and News by PhD's > Cancer Forums and News

Cancer News

Breast
Colon
Kidney
Leukemia
Liver
Lung
Melanoma
Mesothelioma
Myeloma
Neck
Pancreatic
Prostate


Cancer Review

Breast
Colon
Kidney
Leukemia
Liver
Lung
Melanoma
Mesothelioma
Myeloma
Pancreatic
Prostate


Recent Forum Topics

 
Tykerb
Novel drug combo improves breast cancer survival
By gdpawel at 2009-12-13 21:56

SAN ANTONIO -- Some women with very advanced breast cancer may have a new treatment option. A combination of two drugs that more precisely target tumors significantly extended the lives of women who had stopped responding to other medicines, doctors reported Friday.

It was the first big test of combining Herceptin and Tykerbterm. In a study of 300 patients, women receiving both drugs lived nearly five months longer than those given Tykerb alone.

read more | 1523 reads

Antivascular activity of lapatinib and bevacizumab in primary microcluster cultures of breast cancer and other human neoplasms
By gdpawel at 2008-09-12 04:09
 

Antivascular activity of lapatinib and bevacizumabtermterm in primary microcluster cultures of breast cancer and other human neoplasms

Sub-category: New Systemic Agents - New drugs and targets (includes anti-angiogenics) - Other

Category: Treatment

Meeting: 2008 Breast Cancer Symposium

Abstract No: 166

Author(s): L. Weisenthal, D. J. Lee, N. Patel

Abstract:

Background:

The following tyrosine kinase inhibitors (TKI) have been shown to have antivascular (AV) activity: sunitinibterm (Su), sorafenibterm (So), gefitinib (G), erlotinib (E), and imatinib (I). To date, AV activity has not been reported for lapatinib (LAP).

read more | 1 comment | 4300 reads

Commentary highlights impact of food-cancer drug interactions
By Dross at 2007-07-19 00:29
 

Alexandria, Va. – A commentary in the Journal of Clinical Oncology (JCO) urges researchers to explore an intriguing approach to reduce the dose, and therefore the cost, of oral targeted cancer therapies. The commentary, by Mark Ratain, MD and Ezra Cohen, MD of the University of Chicago, examines recent pharmacologic research which found that taking the targeted therapy lapatinib (Tykerbterm) with food significantly increased the concentration of the drug in the body. The commentary suggests that taking lapatinib with food instead of on an empty stomach, as currently indicated, could cut the needed dose by at least 60 percent, reducing the cost accordingly. The authors stress that formal studies are needed to determine the effectiveness of this approach. The article is being published online July 16.

read more | 3 comments | 1522 reads

Phase III Global Study of Tykerb Started for Head and Neck Cancer
By HCat at 2007-02-27 21:35
 

    GlaxoSmithKline has initiated a phase III trial of Tykerbterm in squamous cell carcinomaterm of the head and neck (SCCHN). Phase I results of lapatinib in SCCHN were recently reported at the European Society for Therapeutic Radiology and Oncology (ESTRO). The phase III trial design is based on results in papers from the New England Journal of Medicine found here and here, where researchers investigated post-operative treatment of high-risk SCCHN patients. This trial will compare the effectiveness of oral lapatinib versus placebo given to high-risks patients following surgery.

read more | 2266 reads

Syndicate content
 
Search

sponsored links




Donate


Newsletter



Subscribe to our newsletter to receive info on our site or upcoming clinical trials
Email

Confirm your email address

HTML format
State

Please select the newsletters you want to sign up to:

  • Cancerfocus
    Receive updates from Cancerfocus.
  • Breast
  • Colon
  • Kidney
  • Leukemia
  • Liver
  • Lung
  • Melanoma
  • Mesothelioma
  • Myeloma
  • Neck
  • Pancreatic
  • Prostate




Syndicate
Syndicate content


All times are GMT -5. The time now is 05:17 PM.